ArticleThe Kaohsiung journal of medical sciences2025
Oral Administration of Trichosanthes Kirilowii Fruit Extract Ameliorates Airway Inflammation and Suppresses Th2 Cell Activities in Ovalbumin-Sensitized Mice.
Article in The Kaohsiung journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Oral Administration of Trichosanthes Kirilowii Fruit Extract Ameliorates Airway Inflammation and Suppresses Th2 Cell Activities in Ovalbumin-Sensitized Mice.The Kaohsiung journal of medical sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Trichosanthes kirilowii is a plant used in traditional Chinese medicine. Its fruits, seeds, and roots can all be used medicinally. The fruit of T. kirilowii has a moistening effect on the lung for arresting cough. However, there is no scientific research to prove that the fruit of T. kirilowii can improve asthma. Herein, we evaluated whether T. kirilowii fruit extract (TK) could reduce airway inflammation and airway hyperresponsiveness (AHR) in a murine model of asthma. Female BALB/c mice were sensitized with ovalbumin to induce asthma and treated with varying oral doses of TK from days 14 to 27 of the experiment. Additionally, IL-4/TNF-α-stimulated BEAS-2B cells were treated with different doses of TK to investigate inflammatory cytokine and chemokine secretion. TK treatment significantly mitigated AHR, eosinophil infiltration, and airway inflammation in the lungs of asthmatic mice. It also alleviated goblet cell hyperplasia and lung ROS levels while modulating Th2-associated cytokine levels in the bronchoalveolar lavage fluid. Moreover, TK effectively alleviated proinflammatory cytokine, chemokine, and eotaxin in IL-4 and TNF-α-stimulated BEAS-2B cells. Our results indicate that TK effectively improved asthma symptoms in mice through suppressed Th2-cell activation, which mitigated airway inflammation, oxidative stress, and AHR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.